periodontal disease
Conditions
Interventions
administer ORM twice daily for 4weeks
Sponsors
ROHTO pharmaceutical CO.,LTD
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Patients aged 20 to 64 years on the day of signing the informed consent -Mild to moderate periodontal disease patients
Exclusion criteria
Exclusion criteria: -Patients who have systemic diseases thought to affect evaluation of this study -Patients who have serious oral diease thought to affect evaluation of this study -Patients who smoke
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of periodontal disease index at week4 .Taking photography of oral cavity at week4. | — |
Countries
Japan
Contacts
Public ContactMasahiko Kawai
ROHTO pharmaceutical CO.,LTD Clinical development group Development & Planning office
Outcome results
None listed